NURS 6512 Week 1 Prostate-specific Antigen Test

You are currently viewing NURS 6512 Week 1 Prostate-specific Antigen Test

The present study focuses on the Prostate-specific Antigen (PSA) test, which is an essential tool for advanced practitioners in the field of health assessment and diagnostic reasoning. This test aids in narrowing down the diagnosis and selecting appropriate screening tools based on individual patient factors. The validity and reliability of the PSA test will be evaluated and discussed in detail. During the health interview, the advanced practitioner must ask specific questions to identify potential areas that may require screening or further assessment. Although some of these questions may be uncomfortable for patients, early detection of underlying disease processes can significantly impact their overall well-being. Questions pertaining to family history of prostate disease, urinary issues (such as hesitancy, dribbling, or frequency), and age are crucial in determining the need for a PSA test. Generally, men should undergo a PSA test at the age of fifty, but individuals with a history of prostate cancer may require earlier testing.

NURS 6512 Week 1 Prostate-specific Antigen Test

The PSA test plays a vital role in the detection of prostate cancer, as well as the identification of an enlarged or inflamed prostate. Being a blood test, it can be conveniently performed in any laboratory or physician’s office. However, it is important to note that despite its widespread use, the PSA test has certain limitations. It has a false-positive rate, leading to potential overtreatment and concerns regarding its accuracy. The United States Preventative Services Task Force (USPSTF) recommends against PSA-based screening for prostate cancer in asymptomatic individuals, as it often leads to the detection of clinically insignificant cases. While the PSA test can accurately indicate the presence of prostate cancer, it cannot predict the stage or rate of cancer progression.

Prostate cancer typically progresses slowly, although a small percentage may exhibit aggressive behavior. When discussing the PSA test with patients, practitioners must engage in shared decision-making, considering individual risk factors, family history, and the potential benefits and drawbacks of further testing and treatment. High-risk patients, such as those with a family history or African American ethnicity, may opt for screening, while others may prefer to forgo testing based on their age and life expectancy.


In conclusion, the PSA test serves as a reliable screening tool for prostate cancer, but it is not universally necessary for all aging males. Thorough interviews, including family history assessment, should precede the decision-making process. Awareness of the limitations of the PSA test is crucial in avoiding unnecessary interventions for clinically insignificant cases. NURS 6512 Week 1 Prostate-specific Antigen Test


Ball, J. W., Dains, J. E., Flynn, J. A., Solomon, B. S., & Stewart, R. W. (2019). Seidel’s guide to physical examination: An interprofessional approach (9th ed.). St. Louis, MO: Elsevier Mosby.

Lu, Y.-F., Zhang, Q., Yao, W.-G., Chen, H.-Y., Chen, J.-Y., Xu, C.-C., & Yu, R.-S. (2019). Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data. Cancer Imaging: The Official Publication Of The International Cancer Imaging Society, 19(1), 26.

Moyer, A. V. (2012). Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, (2), 120. Retrieved from